BG104397A - Extended release formulation - Google Patents

Extended release formulation

Info

Publication number
BG104397A
BG104397A BG104397A BG10439700A BG104397A BG 104397 A BG104397 A BG 104397A BG 104397 A BG104397 A BG 104397A BG 10439700 A BG10439700 A BG 10439700A BG 104397 A BG104397 A BG 104397A
Authority
BG
Bulgaria
Prior art keywords
extended release
provides
release formulation
venlafaxine hydrochloride
antidepressant
Prior art date
Application number
BG104397A
Other languages
Bulgarian (bg)
English (en)
Inventor
Deborah M. Sherman
John C. Clark
John U. Lamer
Original Assignee
American Home Products Corp.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25508423&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BG104397(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by American Home Products Corp. filed Critical American Home Products Corp.
Publication of BG104397A publication Critical patent/BG104397A/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5036Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BG104397A 1997-11-05 2000-05-04 Extended release formulation BG104397A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US96432897A 1997-11-05 1997-11-05
PCT/US1998/023338 WO1999022724A2 (fr) 1997-11-05 1998-11-03 Preparation a liberation prolongee

Publications (1)

Publication Number Publication Date
BG104397A true BG104397A (en) 2001-02-28

Family

ID=25508423

Family Applications (1)

Application Number Title Priority Date Filing Date
BG104397A BG104397A (en) 1997-11-05 2000-05-04 Extended release formulation

Country Status (38)

Country Link
EP (1) EP1028718B1 (fr)
JP (1) JP2001521892A (fr)
KR (1) KR20010031797A (fr)
CN (1) CN1278165A (fr)
AR (1) AR014012A1 (fr)
AT (1) ATE237320T1 (fr)
AU (1) AU747978B2 (fr)
BG (1) BG104397A (fr)
BR (1) BR9813179A (fr)
CA (1) CA2305242A1 (fr)
CL (1) CL2004001705A1 (fr)
CO (1) CO5011060A1 (fr)
CZ (1) CZ20001659A3 (fr)
DE (1) DE69813602T2 (fr)
DK (1) DK1028718T3 (fr)
EA (1) EA200000487A1 (fr)
EE (1) EE04577B1 (fr)
ES (1) ES2196620T3 (fr)
GE (1) GEP20043198B (fr)
HR (1) HRP20000213B1 (fr)
HU (1) HU225238B1 (fr)
ID (1) ID26317A (fr)
IL (1) IL135457A0 (fr)
MA (1) MA24691A1 (fr)
NO (1) NO20002126L (fr)
NZ (1) NZ504460A (fr)
PA (1) PA8462501A1 (fr)
PE (1) PE128699A1 (fr)
PL (1) PL341141A1 (fr)
PT (1) PT1028718E (fr)
SK (1) SK6472000A3 (fr)
SV (1) SV1998000131A (fr)
TR (1) TR200001232T2 (fr)
TW (1) TW555568B (fr)
UA (1) UA77145C2 (fr)
UY (2) UY25234A1 (fr)
WO (1) WO1999022724A2 (fr)
ZA (1) ZA9810081B (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60039132D1 (de) * 1999-04-06 2008-07-17 Sepracor Inc O-Desmethylvenlafaxin-Succinat
ATE367153T1 (de) * 1999-05-20 2007-08-15 Elan Corp Plc Multipartikuläre arzneizusammensetzungen mit gesteuerter wirkstoffabgabe enthaltend selektive inhibitoren der serotoninwiederaufnahme
IL146462A (en) * 2001-11-13 2015-02-26 Lycored Bio Ltd Prolonged-release preparations containing as an active compound and analapaxin hydrochloride
CN1630631A (zh) * 2001-12-05 2005-06-22 惠氏公司 新的文拉法星盐酸盐多晶型物及其制备方法
WO2003050074A1 (fr) * 2001-12-13 2003-06-19 Cadila Healthcare Limited Fabrication de l'hydrochlorure venlafaxine et de polymorphes cristallins de celui-ci
WO2003055475A1 (fr) * 2002-01-03 2003-07-10 Lek Pharmaceutical And Chemical Company D.D. Formulation pharmaceutique a liberation controlee contenant de la venlafaxine
US20030190352A1 (en) * 2002-03-28 2003-10-09 Synthon Bv Compositions of venlafaxine base
AU2003219117A1 (en) * 2002-03-28 2003-10-13 Synthon B.V. Extended release venlafaxine formulations
US6696496B2 (en) 2002-03-28 2004-02-24 Synthon Bv Low water-soluble venlafaxine salts
EP1485344A1 (fr) 2002-03-28 2004-12-15 Synthon B.V. Besylate de venlafaxine
FR2845289B1 (fr) 2002-10-04 2004-12-03 Ethypharm Sa Spheroides, procede de preparation et compositions pharmaceutiques.
CA2415154C (fr) * 2002-12-24 2009-06-16 Biovail Laboratories Inc. Preparations a liberation modifiee contenant des inhibiteurs selectifs de la recapture de la serotonine
DE10350194B4 (de) * 2003-10-28 2005-11-10 Bioplanta Arzneimittel Gmbh Verwendung von Extrakten aus Opuntien zur Behandlung von depressiven Verstimmungen und Erkrankungen
TW200503670A (en) * 2003-03-28 2005-02-01 Sandoz Ag Venlafaxine compositions
ATE336988T1 (de) * 2003-07-30 2006-09-15 Pharmathen Sa Venlafaxine hydrochloridformulierungen mit verzögerter freisetzung
HUP0303382A2 (hu) * 2003-10-10 2005-08-29 EGIS Gyógyszergyár Rt. Venlafaxin-hidroklorid-tartalmú pelletek
AU2004315136B2 (en) 2004-02-04 2010-06-17 Alembic Limited Extended release coated microtablets of venlafaxine hydrochloride
US7776358B2 (en) 2004-07-22 2010-08-17 Synthon Ip Inc. Extended release venlafaxine besylate tablets
US20190083399A9 (en) * 2006-04-03 2019-03-21 Isa Odidi Drug delivery composition
WO2007129329A2 (fr) * 2006-05-08 2007-11-15 Jubilant Organosys Limited Préparation pharmaceutique à libération prolongée comprenant du chlorhydrate de venlafaxine
CN102772390B (zh) * 2012-08-16 2014-01-08 乐普药业股份有限公司 一种盐酸文拉法辛缓释胶囊及其制备方法
FR3080278B1 (fr) * 2018-04-11 2021-04-30 Ghs Patents Ltd Procede de fabrication d'un spheroide de cannabidiol

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1561204A (en) * 1977-06-01 1980-02-13 Ici Ltd Sustained release pharmaceutical composition
US6440457B1 (en) * 1993-05-27 2002-08-27 Alza Corporation Method of administering antidepressant dosage form
PE57198A1 (es) * 1996-03-25 1998-10-10 American Home Prod Formula de liberacion prolongada
ZA97976B (en) * 1996-04-05 1997-08-18 Alza Corp Uniform drug delivery theraphy.

Also Published As

Publication number Publication date
HK1029056A1 (en) 2001-03-23
ID26317A (id) 2000-12-14
EA200000487A1 (ru) 2000-10-30
EE04577B1 (et) 2006-02-15
BR9813179A (pt) 2000-08-22
WO1999022724A2 (fr) 1999-05-14
KR20010031797A (ko) 2001-04-16
NO20002126D0 (no) 2000-04-26
CO5011060A1 (es) 2001-02-28
UA77145C2 (en) 2006-11-15
DE69813602T2 (de) 2003-11-06
DK1028718T3 (da) 2003-07-28
EP1028718A2 (fr) 2000-08-23
PE128699A1 (es) 2000-01-06
ZA9810081B (en) 2000-05-04
AR014012A1 (es) 2001-01-31
CL2004001705A1 (es) 2005-06-03
ATE237320T1 (de) 2003-05-15
GEP20043198B (en) 2004-03-25
NZ504460A (en) 2003-01-31
TR200001232T2 (tr) 2000-12-21
SV1998000131A (es) 1999-11-18
CN1278165A (zh) 2000-12-27
PL341141A1 (en) 2001-03-26
CA2305242A1 (fr) 1999-05-14
HUP0004287A2 (hu) 2002-04-29
WO1999022724A3 (fr) 1999-07-22
MA24691A1 (fr) 1999-07-01
AU1300399A (en) 1999-05-24
NO20002126L (no) 2000-05-04
ES2196620T3 (es) 2003-12-16
HU225238B1 (en) 2006-08-28
EP1028718B1 (fr) 2003-04-16
EE200000212A (et) 2001-04-16
JP2001521892A (ja) 2001-11-13
HRP20000213B1 (en) 2004-04-30
IL135457A0 (en) 2001-05-20
DE69813602D1 (de) 2003-05-22
UY25692A1 (es) 2000-03-31
UY25234A1 (es) 2000-12-29
TW555568B (en) 2003-10-01
SK6472000A3 (en) 2000-11-07
HRP20000213A2 (en) 2000-12-31
CZ20001659A3 (cs) 2001-10-17
PT1028718E (pt) 2003-07-31
AU747978B2 (en) 2002-05-30
PA8462501A1 (es) 2000-05-24
HUP0004287A3 (en) 2002-05-28

Similar Documents

Publication Publication Date Title
BG104397A (en) Extended release formulation
CA2199778A1 (fr) Formulation de venlafaxine a liberation prolongee
MY126555A (en) Oral pharmaceutical extended release dosage form
NZ333822A (en) Tramadol multiple unit formulations comprising individual pellets of trmadol coated with one or more membrane layers for controlling release
AU6136199A (en) Dosage form comprising therapeutic formulation
IL116674A (en) Microcrystalline cellulose-based excipient having improved compressibility, pharmaceutical compositions containing the same and methods for the preparation of said excipient and of solid dosage form thereof
NO330947B1 (no) Anvendelse av farmasoytiske sammensetninger som inneholder okskarbazepin, i fastende tilstand
AR052921A1 (es) Uso de ranolazina para la preparacion de una composicion farmaceutica y composicion farmaceutica
WO1994027589A3 (fr) Forme galenique d'un antidepresseur
AU3846901A (en) Oral, nasal and pulmonary dosage formualtions of copolymer 1
PT1411921E (pt) Composições farmacêuticas contendo terbinafina e suas utilizações
GEP20053501B (en) Core Tablet for Controlled Release of Gliclazide after Oral Administration
ATE424810T1 (de) Ein hydrokolloid und einen celluloseether enthaltende tablette mit verzögerter freisetzung
MX2007006212A (es) Medicamento oral para liberacion modificada de al menos un principio activo bajo forma multimicrocapsular.
UA41392C2 (uk) Швидкорозчинна таблетка трамадолу або солі трамадолу
GEP20063882B (en) Dosage regimen and pharmaceutical composition for emergency contraception
ZA985142B (en) Captopril retard.
IL148777A (en) Mirtazepine oral oral administration unit
MX2008006037A (es) Drogas para el sistema nervioso central para administracion una-vez-al-dia.
GEP20043377B (en) Pharmaceutical Complex
AU4469097A (en) Captopril tablets
BG102638A (bg) Таблети с високо съдържание на фамцикловир
ECSP972046A (es) Formula de liberacion prolongada
ECSP982704A (es) Formula de liberacion prolongada
UA83094C2 (en) Tablet of citalopram hydrobromide